These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 24771552)

  • 21. [Clinical significance of new classification of gastroenteropancreatic neuroendocrine neoplasms].
    Zhu XZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jan; 16(1):12-4. PubMed ID: 23691561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
    Niederle MB; Hackl M; Kaserer K; Niederle B
    Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
    Xu JX; Wu DH; Ying LW; Hu HG
    World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
    Alvarado-Cabrero I; de Anda-González J; Hernández-Hernández B; Mantilla-Morales A; Valencia-Cedillo R; Medrano-Guzmán R
    Rev Gastroenterol Mex; 2012; 77(4):174-80. PubMed ID: 23142406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Grading of neuroendocrine tumors].
    Saeger W; Schnabel PA; Komminoth P
    Pathologe; 2016 Jul; 37(4):304-13. PubMed ID: 27379621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
    Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
    Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
    Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
    PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach.
    McDermott S; O'Neill AC; Skehan SJ
    Clin Imaging; 2013; 37(2):194-200. PubMed ID: 23465968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. G3 GEP NENs category: are basic and clinical investigations well integrated?
    Milione M; Fazio N
    Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.
    Klöppel G; Perren A; Heitz PU
    Ann N Y Acad Sci; 2004 Apr; 1014():13-27. PubMed ID: 15153416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).
    Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R;
    Neuroendocrinology; 2019; 108(1):54-62. PubMed ID: 30153658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
    Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
    Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
    Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
    J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
    Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
    Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.